Many important advances have occurred in the field of cancer cachexia over the past decade, including progress in understanding the mechanisms of CACS and the development of promising pharmacologic ...

Though cancer cachexia has been researched extensively, it remains challenging to understand and treat. Though cancer cachexia has been researched extensively, it remains challenging to understand and ...

Pfizer researchers say they are developing a drug that might counteract a condition that leads to the death of cancer patients within a year of its diagnosis. Photo by Stephanie Lecocq/EPA-EFE Sept.

BATON ROUGE, La. (WAFB) - Scientists are eager to find ways to prevent a wasting condition responsible for up to 30% of cancer deaths. A grant from the global funding platform “Cancer Grand Challenges ...

It's estimated that nearly one-third of all cancer deaths are caused not by the cancer itself but by cachexia - a debilitating muscle-wasting syndrome that affects an estimated 80 percent of advanced ...

A new model of cancer-related cachexia promises to help scientists understand why patients with cancer show severe wasting, which in turn may drive the development of better therapies. Cachexia refers ...

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...

The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.

Researchers have discovered a new potential drug target for the lethal wasting disease known as cancer cachexia. Their findings illustrate that even small groups of neurons in the brain can have an ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.